Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

1.895 +0.045 (+2.43%)
Streaming Delayed Price Updated: 3:06 PM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 332,000
Open 1.880
Bid (Size) 1.890 (5,400)
Ask (Size) 1.900 (500)
Prev. Close 1.850
Today's Range 1.855 - 1.950
52wk Range 1.090 - 2.960
Shares Outstanding 17,703,692
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
From INmune Bio, Inc.
Via GlobeNewswire

Performance

YTD
+23.1%
+23.1%
1 Month
+13.8%
+13.8%
3 Month
+28.0%
+28.0%
6 Month
+19.9%
+19.9%
1 Year
-33.6%
-33.6%

More News

Read More
News headline image
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
From INmune Bio, Inc.
Via GlobeNewswire
INMUNE BIO INC (NASDAQ:INMB) Beats Q1 2026 EPS Estimates as Stock Shows Recent Momentum ↗
Via Chartmill
INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial? ↗
Via Stocktwits
News headline image
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio (INMB) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio (INMB) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Topics Economy
News headline image
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is INmune Bio Inc. - Common stock publicly traded?
Yes, INmune Bio Inc. - Common stock is publicly traded.
What exchange does INmune Bio Inc. - Common stock trade on?
INmune Bio Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for INmune Bio Inc. - Common stock?
The ticker symbol for INmune Bio Inc. - Common stock is INMB on the Nasdaq Stock Market
What is the current price of INmune Bio Inc. - Common stock?
The current price of INmune Bio Inc. - Common stock is 1.895
When was INmune Bio Inc. - Common stock last traded?
The last trade of INmune Bio Inc. - Common stock was at 08/04/26 03:06 PM ET
What is the market capitalization of INmune Bio Inc. - Common stock?
The market capitalization of INmune Bio Inc. - Common stock is 33.55M
How many shares of INmune Bio Inc. - Common stock are outstanding?
INmune Bio Inc. - Common stock has 34M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.